Sepsis: Silent Threat Brought to Light
September 1, 2020
This webinar is presented by Dr. Martha Lyon.
About this webinar
With the rapid global spread of the confirmed cases of novel coronavirus SARS-CoV-2, COVID-19 has impacted the healthcare system across the continuum of care. It becomes vital to identify signs of sepsis early, and initiate prompt treatment when diagnosed. Timely intervention may save lives and organ function.
Sepsis is a global health crisis
Sepsis still affects between 47 and 50 million people around the world every year. At least 11 million die – one death every 2.8 seconds[1]. Each year in America, at least 1.7 million develop sepsis, nearly 270,000 Americans die as a result of sepsis and 1 in 3 patients who die in a hospital have sepsis [2]. Sepsis has known to be one of the most expensive health-care problems in America, with a cost of more than $20 billion more than a decade ago [3]. In Canada, sepsis was the 12th leading cause of death in 2011 (with about one in 18 deaths that involved sepsis that year) [4]. This translates to an approximate of $325 million spent annually in Canada to treat patients [5].
Rapid diagnosis of sepsis is paramount to reduce mortality
This webinar will provide updates on prevalence on both neonatal and adults population, but also outline the most recent international, US and Canadian guidelines for sepsis diagnosis and management. With a focus on the importance of the role of clinical laboratory testing including lactate, PCT, CRP, it will discuss their effectiveness and with other biomarkers in both diagnosis and monitoring of sepsis including the preanalytical and analytical requirements for accurate testing. The webinar will also include a brief discussion of the novel approaches to diagnosis and treatment of sepsis during COVID-19.
About the speaker
Dr. Martha Lyon is a Clinical Biochemist who has specialized in Point of Care and Pediatrics since 2000. From 2000 to 2012, Dr. Lyon was the Section Head for Point of Care Testing and Pediatrics with Calgary Laboratory Services at Alberta Children’s Hospital. In 2012, Dr. Lyon moved to Saskatchewan where she accepted a Clinical position in the Department of Pathology and Laboratory Medicine in Saskatoon Health Region. Dr. Lyon became a Diplomat of the American Board of Clinical Chemistry in 1996 and a Fellow of the National Academy of Clinical Biochemistry in 2000.
Who should attend?
- Laboratorians
- Clinical chemists
- Pathologists
- Lab managers and directors
- Point of care coordinators
- Respiratory therapists
- Nurses
- NICU clinicians
- ICU clinicians
- ED clinicians
Continuing education
- One P.A.C.E.® credit-hour will be provided for this session. Radiometer is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
- This session is approved for 1 Florida Laboratory CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563
- Application has been made to the American Association for Respiratory Care (AARC) for continuing education contact hours for respiratory therapists
This webinar will:
- Review the prevalence and impact on neonatal and adults patient healthcare
- Outline the most recent international, US and Canadian definitions and guidelines for treatment and management of sepsis
- Examine the importance of accurate clinical laboratory testing in the diagnosis and monitoring of sepsis treatment
- Discuss antibiotic stewardship in sepsis
- Review novel approaches to diagnosis and treatment of sepsis during COVID-19
1. Global Sepsis Alliance (n.d.). WHAT IS SEPSIS? - DEFINITION OF SEPSIS. Retrieved August 5, 2020, from https://www.global-sepsis-alliance.org/sepsis
2. Centers for Disease Control and Prevention (2020, February 14). Data & Reports. Retrieved August 5, 2020 from https://www.cdc.gov/sepsis/datareports/index.html
3. Kumar G, Kumar N, Taneja A, Kaleekal T, Tarima S, McGinley, et al. Nationwide trends of severe sepsis in the 21st century (2000–2007) Chest. 2011;140:1223–31.
4. Government of Canada (2016, November 23). Health at a GlanceDeaths involving sepsis in Canada Health at a GlanceDeaths involving sepsis in Canada. Retrieved August 05, 2020, from https://www150.statcan.gc.ca/n1/pub/82-624-x/2016001/article/14308-eng.htm
5. Canadian Sepsis Foundation (n.d.). Understanding Sepsis. Retrieved August 05, 2020, from http://canadiansepsisfoundation.ca/understanding-sepsis/.
Radiometer is using Microsoft AZURE Active Directory to authenticate users
Radiometer uses Azure AD to provide our customers and partners secure access to documents, resources, and other services on our customer portal.
If your organization is already using Azure AD you can use the same credentials to access Radiometer's customer portal.
Key benefits
- Allow the use of existing Active Directory credentials
- Single-sign on experience
- Use same credentials to access future services
Request access
You will receive an invitation to access our services via e-mail when your request has been approved.
When you accept the invitation, and your organization is already using AZURE AD, you can use the same credentials to access Radiometer's customer portal. Otherwise, a one-time password will be sent via e-mail to sign in.
Effective Date January 20th, 2023 (last updated January 20th, 2023)
ABOUT THIS POLICY
Radiometer values your privacy and the protection of your personal data. This policy (“Policy”) explains how Radiometer its affiliates, subsidiaries or related companies, a full list of which can be located here (together, “Radiometer”, “our”, “us”, or “we”), collects, uses, shares, transfers and processes data collected from or about you.
“Personal Data” is any information that can be used to directly or indirectly identify an individual or that can be reasonably expected to link to an individual. This can include items such as name, address, telephone number, credit card details, email address, ID number, Internet Protocol (“IP”) address of an electronic device used by an individual, or other identifying code (even absent of other identifying information). Statistical and non-identifiable metric data are not considered Personal Data.
The Radiometer subsidiary, affiliate or related company with which you interact is, where applicable, the data controller (or equivalent under applicable law) responsible for the processing of your Personal Data. You can find a list of the relevant legal entities that act as data controllers in Appendix 1 to this Policy.
SCOPE
This Policy describes the types of Personal Data that we may collect, process or disclose about you and how you may govern this processing by exercising applicable legal rights. This Policy applies to both online and offline information collection, including your use of websites or subdomains operated by us, any mobile applications, when we provide products and/or services to you or notify you about prospective items of interest and in other situations where you interact with us in-person, by telephone or by mail where this Policy is posted or referenced.
There may be occasion where you have been provided with a circumstance-specific privacy notice that is separate from this policy, such as privacy notices for specific activities such as Recruitment. To the extent you were provided with a different notice, those notices apply and govern our interactions with you. If you provide Personal Data about parties other than yourself, you are responsible for ensuring their knowledge of how we will process their personal data, and, where applicable, obtaining any necessary consents required in advance.
We are committed to processing Personal Data in accordance with applicable laws. Please note that if you do not wish to provide your Personal Data to us, some products and/or services may become unavailable to you. Your use of any or all these platforms indicates you have been notified of our collection, use, transfer, and disclosure of your information as described in this Policy to the extent permitted by applicable law.
Read more